Career Updates

Jul 18, 2025 4:58 am

Auron Therapeutics, Inc./LinkedIn

Honored to Partner with LLS Therapy Acceleration Program for Transformative Cancer Therapies – Auron Therapeutics, Inc

Auron Therapeutics, Inc. Shared a Post On LinkedIn

“We’re honored to be supported by The Leukemia & Lymphoma Society through their prestigious Therapy Acceleration Program (TAP)!

LLS TAP’s investment in Auron supports the rapid development of our Phase 1 AUTX-703 for relapsed/refractory acute myeloid leukemia and myelodysplastic syndromes.

This partnership brings more than funding – we gain access to LLS’s unparalleled expertise in blood cancer research and their deep understanding of patient needs. Together, we’re working to bring transformative therapies to patients who need them most.”

Blaine Robinson, Vice President Of Therapy Acceleration Program At The Leukemia & Lymphoma Society, Shared a Post By Auron Therapeutics, Inc., Adding

“Looking forward to working closely with Auron Therapeutics, Inc., our newest biotech partner through our Therapy Acceleration Program (TAP) here at The Leukemia & Lymphoma Society.

A great example of the type of team and company we’re looking for to make investments to help bring innovative therapies to blood cancer patients.”

Stay Informed

Subscribe to OncoDaily Newsletter

Don't miss the latest news in oncology: stay up to date with daily picks from OncoDaily.

Subscribe

• Career Updates

Auron Therapeutics cancer LLS Therapy Acceleration Program OncoDaily Oncology The Leukemia & Lymphoma Society